Overview

Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk Features

Status:
Not yet recruiting

Trial end date:
2027-12-20

Target enrollment:

Participant gender:

Summary

The goal of this study is to reduce cisplatin-induced ototoxicity with sodium thiosulfate (STS) in children (ages 4-21 years) with newly-diagnosed average-risk and low-risk medulloblastoma. This trial will also evaluate the tumor protection potential of STS in a disease-focused setting by monitoring survival against a carefully selected historical control cohort treated identically using the ACNS0331 backbone.

Phase:

Phase 3

Details

Lead Sponsor:

Children's Oncology Group

Collaborator:

National Cancer Institute (NCI)

Treatments:

Cyclophosphamide
Lomustine
Sodium thiosulfate
Vincristine